Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H24N4O.C6H8O7 |
| Molecular Weight | 564.5864 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.CN1C\C=C\CCOC2=CC(=CC=C2)C3=CC=NC(NC4=CC=CC(C1)=C4)=N3
InChI
InChIKey=NWYDRHSNEATNRI-SQQVDAMQSA-N
InChI=1S/C23H24N4O.C6H8O7/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27;7-3(8)1-6(13,5(11)12)2-4(9)10/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b3-2+;
| Molecular Formula | C23H24N4O |
| Molecular Weight | 372.4629 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H8O7 |
| Molecular Weight | 192.1235 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:24:47 UTC 2023
by
admin
on
Fri Dec 15 20:24:47 UTC 2023
|
| Record UNII |
3VF50SU4RZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1204918-73-9
Created by
admin on Fri Dec 15 20:24:47 UTC 2023 , Edited by admin on Fri Dec 15 20:24:47 UTC 2023
|
PRIMARY | |||
|
SUB193166
Created by
admin on Fri Dec 15 20:24:47 UTC 2023 , Edited by admin on Fri Dec 15 20:24:47 UTC 2023
|
PRIMARY | |||
|
1321626-26-9
Created by
admin on Fri Dec 15 20:24:47 UTC 2023 , Edited by admin on Fri Dec 15 20:24:47 UTC 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
FG-157
Created by
admin on Fri Dec 15 20:24:47 UTC 2023 , Edited by admin on Fri Dec 15 20:24:47 UTC 2023
|
PRIMARY | |||
|
C105851
Created by
admin on Fri Dec 15 20:24:47 UTC 2023 , Edited by admin on Fri Dec 15 20:24:47 UTC 2023
|
PRIMARY | |||
|
87368269
Created by
admin on Fri Dec 15 20:24:47 UTC 2023 , Edited by admin on Fri Dec 15 20:24:47 UTC 2023
|
PRIMARY | |||
|
100000177624
Created by
admin on Fri Dec 15 20:24:47 UTC 2023 , Edited by admin on Fri Dec 15 20:24:47 UTC 2023
|
PRIMARY | |||
|
3VF50SU4RZ
Created by
admin on Fri Dec 15 20:24:47 UTC 2023 , Edited by admin on Fri Dec 15 20:24:47 UTC 2023
|
PRIMARY | |||
|
TG-02 CITRATE
Created by
admin on Fri Dec 15 20:24:47 UTC 2023 , Edited by admin on Fri Dec 15 20:24:47 UTC 2023
|
PRIMARY | SB1317(TG-02) is a novel small molecule potent CDK2/JAK2/FLT3 inhibitor with IC50s of 13/73/56 nM respectively.; IC50 Value: 13/73/56 nM(CDK2/JAK2/FLT3); Target: CDK2/JAK2/FLT3; TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |